Activation of the kallikrein–kinin system due to the down-regulation of ACE2 on endothelial cells might contribute to the pathophysiology of COVID-19, which suggests that inhibition of the kallikrein–kinin system might improve clinical outcomes of COVID-19 [209]. The gene discussed is KLK4; the disease is COVID-19.